Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma

11:27 EDT 15 Apr 2019 | ecancermedicalscience

Prof Sandip Patel speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the DART study, which examined the administration of ipilimumab plus nivolumab to achieve dual checkpoint inhibition in a cohort of patients with...

More From BioPortfolio on "Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma"